In contrast to targeted therapy for BRAF V600E/K mutant melanomas, immune checkpoint inhibitors (ICI) have shown enhanced clinical outcomes in melanoma patients irrespective of the presence of a particular oncogenic mutational signature or biomarker12,13. The gene discussed is BRAF; the disease is melanoma.